Founded in 2016, Opticyte, Inc. is a medical device innovator based in Seattle, WA, and a spinoff from the University of Washington. The company's core mission is to prevent organ failure through early detection of low oxygen levels in cells. Opticyte leverages proprietary advanced algorithms and tailored optical spectroscopy technology to develop its flagship product, the Cell O2 Monitor. This device aims to transform the standard of care for conditions like sepsis by providing real-time, accurate measurements of cell oxygen levels across all skin tones.

Opticyte's team comprises experienced professionals in engineering, regulatory affairs, and communications, dedicated to bringing this groundbreaking medical technology to market. The company has garnered attention for its potential to significantly reduce the global burden of organ failure, which includes millions of sepsis cases and related deaths annually. By offering a solution that enhances early detection and timely treatment, Opticyte is poised to make a substantial impact on patient care and public health worldwide.